RadioS Cancer Research Results

RadioS, RadioSensitizer: Click to Expand ⟱
Source:
Type:
A radiosensitizer is an agent that makes cancer cells more sensitive to the damaging effects of radiation therapy. By using a radiosensitizer, clinicians aim to enhance the effectiveness of radiation treatment by either increasing the damage incurred by tumor cells or by interfering with the cancer cells’ repair mechanisms. This can potentially allow for lower doses of radiation, reduced side effects, or improved treatment outcomes.
Pathways that help Radiosensitivity: downregulating HIF-1α, increase SIRT1, Txr

List of Natural Products with radiosensitizing properties:
-Curcumin:modulate NF-κB, STAT3 and has been shown in preclinical studies to enhance the effects of radiation by inhibiting cell survival pathways.
-Resveratrol:
-EGCG:
-Quercetin:
-Genistein:
-Parthenolide:

How radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including:
-gold nanoparticles (GNPs),
-gold triethylphosphine cyanide ([Au(SCN) (PEt3)]),
-auranofin, ceria nanoparticles (CONPs),
-curcumin and its derivatives,
-piperlongamide,
-indolequinone derivatives,
-micheliolide,
-motexafin gadolinium, and
-ethane selenide selenidazole derivatives (SeDs)
Park, Parkinson's Disease (PD): Click to Expand ⟱
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms, and is due to the degeneration of dopaminergic neurons. It is multifactorial, caused by genetic and environmental factors and currently has no definitive cure.
-CoQ10 deficiency was observed at a higher frequency in Parkinson's disease
Scientific Papers found: Click to Expand⟱
2731- BetA,    Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives
- Review, GBM, NA - Review, Park, NA - Review, AD, NA
BBB↑, *GSH↑, *Catalase↑, *motorD↑, *neuroP↑, *cognitive↑, *ROS↓, *antiOx↑, *Inflam↓, MMP↓, STAT3↓, NF-kB↓, Sp1/3/4↓, TOP1↓, EMT↓, Hif1a↓, VEGF↓, ChemoSen↑, RadioS↑, BioAv↓,
6542- BSB,    Health Benefits, Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of α-Bisabolol
- Review, Var, NA - Review, Park, NA - Review, AD, NA
AntiCan↑, *neuroP↑, *cardioP↑, *AntiBio↑, *BioAv↑, *toxicity↓, *BioAv↑, *motorD↑, *SOD↑, *Catalase↑, *Keap1↑, *MDA↓, *GSH↑, *IL1β↓, *IL6↓, *TNF-α↓, *iNOS↓, *COX2↓, *lipid-P↓, *Cyt‑c↓, *ROS↓, *MMP↑, *antiOx↑, *AChE↓, *Apoptosis↓, *BAX↓, *Casp3↓, *Bcl-2↑, *BACE↓, *BChE↓, *eff↑, *Aβ↓, *ATP↑, RadioS↑, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Apoptosis↑, PARP↑, BAX↑, BID↑, NF-kB↑, Fas↑, EGFR↑, TIMP2↑, XIAP↓, COX2↓, Bak↓, Bcl-2↓, P53↑, HER2/EBBR2↓, FGF↓, CEA↓, Akt↓, TumCCA↑, *Imm↑, *CD4+↑, *CD8+↑, *BBB↑, *Pain↓, *cardioP↑, *TBARS↓, *SOD↑, *Catalase↑, *GSH↑, *AntiBio↑, *AntiFungal↑, *GastroP↑, *RenoP↑, *creat↓, *uricA↓, *Inflam↓, *iNOS↓, *COX2↓, *TNF-α↓, *IL6↑, *MMP13↓,
5943- Cela,    Celastrol: A Spectrum of Treatment Opportunities in Chronic Diseases
- Review, Arthritis, NA - Review, IBD, NA - Review, AD, NA - Review, Park, NA
*other↝, *other↝, *CRP↓, *eff↝, *other↑, *CXCR4↓, *IL1β↓, *IL6↓, *IL17↓, *IL18↓, *TNF-α↓, *MMP9↓, *PGE2↓, *COX1↓, *COX2↓, *PI3K↓, *Akt↓, *other↑, TumCCA↑, Apoptosis↑, ROS↑, JNK↑, TumAuto↑, Hif1a↓, BNIP3↝, HSP90↓, Fas↑, FasL↑, ETC↓, VEGF↓, angioG↓, RadioS↑, *neuroP↑, *HSP70/HSPA5↑, *ROS↓, *MMP↑, *Cyt‑c↓, *Casp3↓, *Casp9↓, *MAPK↓, *Dose⇅, *HSPs↑, BioAv↓, Dose↝,
2782- CHr,    Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
- Review, Var, NA - Review, Stroke, NA - Review, Park, NA
*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, eff↑, eff↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, eff↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NRF2↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

ETC↓, 1,   MMP↓, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 3,   Bak↓, 1,   BAX↑, 2,   Bcl-2↓, 1,   BID↑, 1,   Casp3↑, 2,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 2,   Fas↑, 2,   FasL↑, 1,   hTERT/TERT↓, 1,   JNK↑, 1,  

Kinase & Signal Transduction ⓘ

HER2/EBBR2↓, 1,   Sp1/3/4↓, 1,  

Protein Folding & ER Stress ⓘ

eIF2α↑, 1,   ER Stress↑, 1,   HSP90↓, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↝, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,   PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   FGF↓, 1,   Let-7↑, 1,   NOTCH1↑, 1,   SHP1↑, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   TOP1↓, 1,  

Migration ⓘ

Ca+2↑, 1,   CEA↓, 1,   E-cadherin↑, 1,   N-cadherin↓, 1,   TET1↑, 1,   TIMP2↑, 1,   TumCP↓, 1,   TumMeta↓, 1,   Twist↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   ATF4↑, 1,   EGFR↑, 1,   Hif1a↓, 2,   VEGF↓, 3,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 2,   NF-kB↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   ChemoSen↑, 1,   Dose↝, 1,   eff↑, 4,   RadioS↑, 4,  

Clinical Biomarkers ⓘ

CEA↓, 1,   EGFR↑, 1,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,  
Total Targets: 76

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiBio↑, 2,  

Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 3,   GSH↑, 3,   Keap1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   ROS↓, 4,   SOD↑, 2,   TBARS↓, 1,   uricA↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   MMP↑, 2,  

Core Metabolism/Glycolysis ⓘ

lipidLev↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↓, 1,   BAX↓, 1,   Bcl-2↑, 1,   Casp3↓, 2,   Casp9↓, 1,   Cyt‑c↓, 2,   iNOS↓, 2,   MAPK↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 2,   other↝, 2,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↑, 1,   HSPs↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 2,  

Migration ⓘ

MMP13↓, 1,   MMP9↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   GastroP↑, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   COX1↓, 1,   COX2↓, 3,   CRP↓, 1,   CXCR4↓, 1,   IL17↓, 1,   IL18↓, 1,   IL1β↓, 2,   IL2↓, 1,   IL6↓, 2,   IL6↑, 1,   Imm↑, 1,   Inflam↓, 3,   PGE2↓, 1,   TNF-α↓, 4,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,   BChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 2,   Dose⇅, 1,   eff↑, 1,   eff↝, 1,  

Clinical Biomarkers ⓘ

creat↓, 1,   CRP↓, 1,   IL6↓, 2,   IL6↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 3,   cognitive↑, 2,   hepatoP↑, 1,   motorD↑, 2,   neuroP↑, 4,   Pain↓, 1,   RenoP↑, 2,   toxicity↓, 1,  

Infection & Microbiome ⓘ

AntiFungal↑, 1,   CD8+↑, 1,  
Total Targets: 70

Scientific Paper Hit Count for: RadioS, RadioSensitizer
1 Betulinic acid
1 α-Bisabolol / Chamomile oil
1 Celastrol
1 Chrysin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:75  Cells:%  prod#:%  Target#:1107  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page